Without disclosing full Phase Ib data, the company reported a higher-than-expected placebo response versus IMU-935. With its second setback this year Immunic has a long path to meaningful data.

Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.

The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.